Helping GV20 to achieve full chain management from domestic R&D of anticancer drugs to the US market
-
Biomedical
-
Precision Cancer Therapy
-
China R&D / China-US Sales
GV20
-
New ‘anti-cancer’ targets
-
Focusing on ‘non-druggable’ targets
-
Cold Targets
-
Functional Genomics
-
Antibody Discovery Platform
-
Small Molecule Drug Development
-
Customer Profile
GV20 Oncotherapy (GV20 Bio) is a biotechnology company focused on the research and development of precision cancer therapies with a unique focus on novel target identification and antibody drug discovery in immuno-oncology, founded in 2016 and headquartered in Shanghai, China, with a branch office in the United States.
-
Informatics Challenges
1.Satisfy the internationalisation (Chinese and American markets) integration management requirements;
2.GSP/GMP management requirements;
3.R & D, cost and inventory management;
4.Future global trade expansion requirements.
-
Solutions
1.NetSuite internationalisation and conglomerate attributes naturally meet GV20 conglomerate internationalisation management requirements;
2.NetSuite meets the management requirements of GSP and GMP, batch traceability of materials, semi-finished products and finished products, and inventory maintenance;
3.R & D stage management: R & D stage (no product has entered the late stage of clinical), project management in the R & D process, R & D cost management such as materials, labour and fees, inventory management and inventory maintenance of the two subsidiaries in the United States and China;
4.NetSuite itself has a full range of functional modules to meet the future from R & D to global trade management compatible management.
